Major Depressive Disorder

Bipolar depression can be difficult to treat and is often misdiagnosed.

Despite being commonly prescribed as an antidepressant, investigators find sertraline more effective at alleviating anxiety symptoms.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

A clinical discussion on the underlooked, undertreated, and underperforming facets of a public health crisis.

Acadia Pharmaceuticals has announced positive findings for time to psychosis relapse in dementia patients, which resulted in the trial's early end.

Recent research advances have associated the gut's health to overall patient health. What do we know now?

After success in multiple clinical trials, officials tout esketamine as a treatment for both major depressive disorder with active suicidal ideation and treatment resistant depression.

Investigators report positive results using esketamine spray to treat patients with major depressive disorder.

A study of human gut bacteria suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression.

In a double-blind, phase 2 trial, investigators find that SAGE-17 results in a reduction of depressive symptoms after 2 weeks.

In honor of National Suicide Prevention Week, Simon Rego, PsyD, and colleagues from Montefiore will look at suicide from a public health and clinical scope.

A new set of 22 recommendations include a combination of universal screenings, medication, and other preventative initiatives in an effort to drive down veteran suicide rates.

Despite a common belief that medications treating mental illnesses are connected to weight gain, new data shows an individual in a weight management program will lose weight whether or not they are taking antidepressants or antipsychotics.

A pattern of poor sleep could lead to worsened psychiatric wellbeing—and eventually, memory loss.

In a new study, investigators examine the efficacy and tolerability of antipsychotic medications for patients in remission for psychotic depression.

In an extensive population-based study, investigators link children with IBD with an increased risk of any psychiatric disorder.

The association of depression symptoms with cognition and cortical amyloid measurements could lead to better therapies to prevent Alzheimer disease.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

This week's #DocTalk tweet chat generated discussion on the means by which healthcare professionals can influence mental health policies and understanding.

A conventional mass-univariate fMRI analysis helps determine patients that exhibit greater pretreatment neural activity.

New research shows esketamine nasal spray could help treat patients who do not respond to antidepressants.

New research finds association common sleep disorder present in 14% of suicidal patients with major depressive disorder studied.

Investigators examined more than 3500 adolescents and found associations between computer and social media use, but not video game and television use.

A recent study found that young people with life-limiting conditions had higher prevalence rates of both anxiety and depression.

A recent study found that depression among caregivers was associated with a 73% increased risk of emergency department visits in patients with dementia.

A recent study of more than 50,000 found that antidepressant use could reduce a third of deaths among diabetic patients with depression.

A recent study found that every year of education was equivalent to a 2.5% reduction in risk of heart disease.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

The nasal spray was shown to reduce relapse in patients who achieved remission or stability after 16 weeks of treatment plus antidepressant.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.